Kolmar Korea Co (161890) Fair Value & Analysis
Consumer Defensive · KR · Market cap 2.0T KRW
Analysis
Kolmar Korea Co (161890) currently trades at 83,400 KRW, while our model-based Fair Value estimate is 111,275 KRW — implying the stock looks roughly 33.4% undervalued today. We read business quality at 80/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
About the company
Kolmar Korea Co., Ltd. researches, develops, produces, and sells beauty and health products in South Korea and internationally. It offers skincare cosmetic products, including toners, lotions, ampoules, essences, creams, mask sheets, mask packs, and lip balms; fragrance products, such as perfumes, and cleansing products; body and hair products; and color cosmetic products comprising makeup bases, primers, foundation and concealers, cushion foundations, and mascaras. The company also provides powder base products, such as eye shadows, powder pacts, highlighters, blushers, shadings, loose powders, jelly powders, wet powders, multi-color concurrent forming, gradations, marble teracotas, hair cushions, essence powders, bubble salts, eyebrow pencils, highlighters, etc.; and oil & emulsification base products, including lip sticks, lip balms, lip glosses, tints, essence pacts, stick foundations, sun sticks, skin covers, gel eyeliners, marble essence pacts, core sticks, two-tone sticks, ma…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.